We performed the xenograft experiment using PATU8902 harboring the KRAS(G12V) mutation, because targeting KRAS(G12V)-driven cancer is an unmet need whereas multiple G12C covalent inhibitors exist that are effective against KRAS(G12C) in xenograft experiments6,9. Here, KRAS is linked to cancer.